What is ADMA Biologics's common stock shares authorized?

ADMA Biologics (ADMA) reported common stock shares authorized of 4.7M in Q4 2025.

What does common stock shares authorized mean?

This represents the maximum number of common stock shares that the company is legally permitted to issue under its corporate charter. It defines the upper limit of the company's equity base and its capacity for future capital raises.

ADMA Biologics ADMA Common Stock Shares Authorized

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's common stock shares authorized.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's common stock shares authorized?: ADMA Biologics (ADMA) reported common stock shares authorized of 4.7M in Q4 2025.
What does common stock shares authorized mean?: This represents the maximum number of common stock shares that the company is legally permitted to issue under its corporate charter. It defines the upper limit of the company's equity base and its capacity for future capital raises.